stockrowMedpace Holdings, Inc.
MEDP Healthcare Diagnostics & Research
Medpace Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.5 billion, up 20.0% from fiscal 2024.
- Revenue
- +8.50%
- EPS
- +24.6%
- Free cash flow
- −16.6%
Quarter to September 2026, against a year earlier
Follow MEDP
Alert me
Medpace Holdings, Inc. (MEDP) Total debt
Medpace Holdings, Inc.'s total debt at the end of fiscal 2022 was $50.0M, up 212.5% from $16.0M in fiscal 2021. At the end of the quarter to 30 September 2023 it was $163.0M. Over the past ten years it has ranged from $11.0M (fiscal 2019) to $408.2M (fiscal 2015); the current reading is higher than 50% of that period. Medpace Holdings, Inc. ranks 21st of 46 Diagnostics & Research companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2022 | $50.0M | 212.50% |
| FY2021 | $16.0M | 0.00% |
| FY2020 | $16.0M | 45.45% |
| FY2019 | $11.0M | (89.64%) |
| FY2018 | $106.2M | (57.21%) |
| FY2017 | $248.2M | 29.16% |
| FY2016 | $192.2M | (52.92%) |
| FY2015 | $408.2M | — |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Sep 2023 | $163.0M | 196.36% |
| Jun 2023 | $55.0M | (52.17%) |
| Mar 2023 | $115.0M | 130.00% |
| Dec 2022 | $50.0M | (64.21%) |
| 25 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| DGX Quest Diagnostics Incorporated compare | $5.6B |
| LH Labcorp Holdings Inc. compare | $5.3B |
| ICLR ICON PLC compare | $3.4B |
| RVTY Revvity Inc. compare | $2.6B |
| CRL Charles River Laboratories International, Inc. compare | $2.4B |
| ILMN Illumina, Inc. compare | $1.8B |
| QGEN QIAGEN N.V. compare | $1.6B |
| GH Guardant Health, Inc. compare | $1.5B |
| MEDP Medpace Holdings, Inc. | $163.0M |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on MEDP
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement